Response and Resistance to Menin Inhibitor in UBTF –Tandem Duplication AML
- 27 June 2024
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 390 (24) , 2323-2325
Abstract
No abstract availableFunding Information
- Wilson Centre for Blood Cancer Genomics
- National Health and Medical Research Council (Synergy ID GNT2011139)
- Snowdome Foundation
This publication has 5 references indexed in Scilit:
- Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitorsBlood, 2024
- MEN1 mutations mediate clinical resistance to menin inhibitionNature, 2023
- The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaNature, 2023
- Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid LeukemiaBlood Cancer Discovery, 2022
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AMLBlood, 2020